<DOC>
	<DOCNO>NCT00006455</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know combination chemotherapy regimen effective treat anaplastic large cell lymphoma . PURPOSE : This randomized phase III trial study several different regimen combination chemotherapy compare well work treat child anaplastic large cell lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Children With Anaplastic Large Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare event-free survival child anaplastic large cell lymphoma treat various induction maintenance chemotherapy regimens without vinblastine . - Compare impact different dos schedule methotrexate Berlin-Frankfurt-Munster-K2 Protocol term overall survival , complete remission rate , CNS relapse rate , nonlymphoma-related death early death rate patient . OUTLINE : This randomize , multicenter study . Patients stratify accord country , vinblastine ( VBL ) ( yes v ) , prognostic factor ( standard-risk ( SR ) vs high-risk ( HR ) disease ) . Beginning immediately confirmation diagnosis , patient receive prephase therapy comprise dexamethasone ( DM ) IV orally daily day 1 2 every 12 hour day 3-5 ; cyclophosphamide ( CTX ) IV 1 hour day 1 2 ; methotrexate ( MTX ) intrathecally ( IT ) , doxorubicin ( DOX ) IV , hydrocortisone ( HC ) IT day 1 . Patients assign one two treatment group base prognosis : - Group 1 ( SR disease ) : Patients randomize arm I III : - Arm I : Patients receive treatment arm I define day 1 , follow course define follow order begin day 6 : A1 , B1 , A2 , B2 , A3 , B3 . - Arm III : Patients receive treatment arm III define day 1 , follow course define follow order begin day 6 : regimen AM1 , BM1 , AM2 , BM2 , AM3 , BM3 . - Group 2 ( HR disease ) : - First randomization : Patients randomize arm I III : - Arm I : Patients receive treatment arm I define day 1 course A1 define day 6 . - Arm III : Patients receive treatment arm III define day 1 course AM1 define day 6 . - Second randomization : Patients without disease progression completion therapy randomize arm I , II , III , IV . - Arm I : Patients receive treatment arm I define day 1 , follow course define follow order blood count recover : B1 , A2 , B2 , A3 , B3 . - Arm II : Patients receive treatment arm II define day 1 , follow course define follow order blood count recover : BV1 , AV2 , BV2 , AV3 , BV3 . - Arm III : Patients receive treatment arm III define day 1 , follow course define follow order blood count recover : BM1 , AM2 , BM2 , AM3 , BM3 . - Arm IV : Patients receive treatment arm IV define day 1 , follow course define follow order blood count recover : BMV1 , AMV2 , BMV2 , AMV3 , BMV3 . Patients follow every 2 month 1 year , every 4 month 2 year , every 6 month 2 year , annually thereafter . DEFINITIONS : - Arms I-IV define : - Arm I : Patients receive low dose MTX IV 24 hour MTX IT . - Arm II : Patients receive low dose MTX IV 24 hour MTX IT . Patients HR disease also receive VBL IV weekly 1 year begin 3 week initiation course BV3 . - Arm III : Patients receive high dose MTX IV 3 hour without intrathecal therapy . - Arm IV : Patients receive treatment arm III . Patients HR disease also receive VBL IV weekly 1 year begin 3 week initiation course BMV3 . - Regimens A , B , AV , BV , AM , BM , AMV , BMV define : - Regimen A ( course A1 , A2 , A3 ) : Patients receive DM IV orally every 12 hour day 1-5 ; MTX IV 24 hour day 1 ; MTX IT , DOX IV HC IT ( begin 2-4 hour initiation MTX infusion ) day 1 ; leucovorin calcium ( CF ) IV rescue 42 , 48 , 54 hour initiation MTX infusion ; ifosfamide ( IFF ) IV 1 hour day 1-5 ( initiation MTX infusion ) ; cytarabine ( ARA-C ) IV 1 hour every 12 hour etoposide ( VP-16 ) IV 2 hour ( begin completion ARA-C infusion ) day 4 5 . Each course last 3 week . - Regimen B ( course B1 , B2 , B3 ) : Patients receive DM , MTX , intrathecal therapy , CF rescue regimen A . Patients also receive CTX IV 1 hour day 1-5 DOX IV 1 hour day 4 5 . Each course last 3 week . - Regimen AV ( course AV1 , AV2 , AV3 ) : Patients receive treatment regimen A VBL IV day 1 . Each course last 3 week . - Regimen BV ( course BV1 , BV2 , BV3 ) : Patients receive treatment regimen B VBL IV regimen AV . Each course last 3 week . - Regimen AM ( course AM1 , AM2 , AM3 ) : Patients receive DM IV orally every 12 hour day 1-5 ; MTX IV 3 hour day 1 ; CF IV rescue every 6 hour total 12 dos begin 24 hour initiation MTX infusion . Patients also receive IFF , ARA-C , VP-16 regimen A . Each course last 3 week . - Regimen BM ( course BM1 , BM2 , BM3 ) : Patients receive CTX DOX regimen B . Patients also receive DM , MTX , CF rescue regimen AM . Each course last 3 week . - Regimen AMV ( course AMV1 , AMV2 , AMV3 ) : Patients receive treatment regimen AM VBL regimen AV . Each course last 3 week . - Regimen BMV ( course BMV1 , BMV2 , BMV3 ) : Patients receive treatment regimen BM VBL regimen AV . Each course last 3 week . PROJECTED ACCRUAL : A total 400 patient accrue study within 5.4-6.7 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove standardrisk ( SR ) highrisk ( HR ) anaplastic large cell lymphoma SR disease define involvement skin , mediastinum , liver , spleen , lung HR disease define follow : Biopsy proven skin lesion ( except skin lesion overlie involved node isolated skin disease ) Mediastinal involvement xray CT scan Involvement liver ( enlarge least 5 cm and/or nodular ) , spleen ( enlarged and/or nodular ) , lung ( biopsy need obvious lesion ) Histologic cytologic slide must available national pathology review patient meet classical criterion diagnosis ( typical histopathology , immunohistochemistry : CD30 positive , endomysial antibody positive , nucleophosmin negative , anaplastic lymphoma kinase ( ALK ) positive ( available ) , null Timmunophenotype ) unless prove ( 2 ; 5 ) Must enroll within 1 week prior begin study regimen A No CNS involvement ( CSF cerebral tumor ) First randomization ( SR HR disease ) : Must begin prephase therapy No isolate primary skin disease No lowrisk disease define completely resected stage I disease Second randomization ( HR disease ) : Must complete first randomization therapy without disease progression PATIENT CHARACTERISTICS : Age : Under 22 Performance status : Not specify Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : See Disease Characteristics Renal : Not specify Pulmonary : See Disease Characteristics Immunologic : No congenital immunodeficiency No AIDS Other : No prior malignancy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Prior corticosteroid anaplastic large cell lymphoma allow give 8 day Radiotherapy : Not specify Surgery : No prior organ transplantation Other : No prior therapy anaplastic large cell lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>stage I childhood anaplastic large cell lymphoma</keyword>
	<keyword>stage II childhood anaplastic large cell lymphoma</keyword>
	<keyword>stage III childhood anaplastic large cell lymphoma</keyword>
	<keyword>stage IV childhood anaplastic large cell lymphoma</keyword>
	<keyword>recurrent childhood anaplastic large cell lymphoma</keyword>
</DOC>